AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03722914
Drug: blank control 0mg
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/pellet, 1pellet/time, 3times/day
Trial: NCT04545788
Drug: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
Trial: NCT01112423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Trial: NCT01709981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
Trial: NCT01240408
Drug: HOPE
RxNorm normalized name: LIQUID HOPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
Trial: NCT01240408
Drug: HOPE
RxNorm normalized name: LIQUID HOPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
Trial: NCT01309438
Drug: Erythromycin (normal renal function)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
Trial: NCT01309438
Drug: Erythromycin (mild and moderate renal function)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
Trial: NCT00001449
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01763866
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally once a day
Trial: NCT01763866
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally once a day
Trial: NCT03971500
Drug: AntiPlatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
Trial: NCT02637726
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil at discretion of the anesthesiologist
Trial: NCT01352065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 10 mg per day, single per day, 8 weeks
Trial: NCT04275050
Drug: TQB3303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
Trial: NCT00141557
Drug: esterified estrogens 1.25mg and methyltestosterone 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESTRATEST® administered orally QD
Trial: NCT03485092
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets for oral self administration once a day
Trial: NCT03143972
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single drug administration
Trial: NCT00006372
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT02492087
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Normal saline 0.9% 120mls solution
Trial: NCT02905058
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral non-steroidal antiinflammatory drug
Trial: NCT02905058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017095
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00476996
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00476996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01148316
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
Trial: NCT00017095
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00082043
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05049447
Drug: Pascoflair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 2 tablets (single-dose)
Trial: NCT00305747
Drug: BR-DIM
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
Trial: NCT02679196
Drug: KA2237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3 Kinase p110β/δ inhibitor
Trial: NCT02501837
Drug: Syntocinon-Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 24 IU Oxytocin
Trial: NCT01711541
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00992732
Drug: HQK-1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Trial: NCT02204813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours.
Trial: NCT02204813
Drug: Lo-Xenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours.
Trial: NCT00225147
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT01867645
Drug: IgM-enriched Intravenous Immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
Trial: NCT03713216
Drug: Naldebain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Nalbuphine sebacate
Trial: NCT00698035
Drug: Testosterone Cream
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
Trial: NCT00861588
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch placebo
Trial: NCT02825147
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01287546
Drug: LY2875358
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
Trial: NCT00209170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sugar pill taken as one to two tablets daily for 6 months.
Trial: NCT02317341
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously over 40 minutes
Trial: NCT01959399
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01959399
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT00442676
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, 200 mg/day until 32 weeks of gestation
Trial: NCT00442676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules of lactose
Trial: NCT01933256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00645918
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
Trial: NCT02538367
Drug: YH12852 IR 0.05mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538367
Drug: YH12852 IR 0.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538367
Drug: YH12852 DR1 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538367
Drug: YH12852 DR2 8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04008901
Drug: BST-104 (Lonicera Flos Extract)
RxNorm normalized name: Lonicera japonica top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg of Lonicera Flos extract in 1 tablet (300 mg)
Trial: NCT04008901
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of Lonicera Flos extract in 1 tablet (300 mg)
Trial: NCT02029638
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume.
Trial: NCT02029638
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg orally prior to antithymocyte globulin infusion.
Trial: NCT00684112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
Trial: NCT04387526
Drug: (SOF and DCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04387526
Drug: (SOF, DCV, and RBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00249977
Drug: Capecitabine in Combination with Cisplatin and Irinotecan
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2.
Trial: NCT00237445
Drug: telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00237445
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04198233
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository
Trial: NCT04504435
Drug: GSK3494245
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
Trial: NCT04504435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules will be provided
Trial: NCT01965912
Drug: Kuvan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
Trial: NCT01224587
Drug: D1000078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, one single dose
Trial: NCT01224587
Drug: D1000082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, one single dose
Trial: NCT01224587
Drug: D1000083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, one single dose
Trial: NCT01224587
Drug: D1000085
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, one single dose
Trial: NCT01442532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=tablet, route=oral use, for 14 days
Trial: NCT00729326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Trial: NCT00729326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (100mg), once a day in the morning
Trial: NCT03034408
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01963754
Drug: Subperiosteal 1:100.000 Articaine 4% epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of subperiosteal anesthesia for implant placement
Trial: NCT03843736
Drug: Probiotic Agent
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
Trial: NCT00005848
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib Placebo tablets given twice a day
Trial: NCT00862121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening
Trial: NCT01338883
Drug: Sustiva + Truvada
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustiva plus Truvada
Trial: NCT02555657
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00599027
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray once daily (two puffs per nostril) in the morning.
Trial: NCT02067416
Drug: Anthracycline based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care neoadjuvant treatment with anthracycline based chemotherapy
Trial: NCT01230749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Trial: NCT01769469
Drug: FTC/TDF (Truvada®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
Trial: NCT02394795
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT02394795
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT02392494
Drug: MK-1075
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
Trial: NCT01383967
Drug: LY2979165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01383967
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00984880
Drug: AZD3043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
Trial: NCT00532428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02713789
Drug: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02713789
Drug: Placebo (PBS-20% sucrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03789890
Drug: BAY1902607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
Trial: NCT04344379
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg per day
Trial: NCT00131664
Drug: Avandia and Amaryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
Trial: NCT00336778
Drug: 3TC, TDF, NLV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
Trial: NCT04492878
Drug: IKERVIS®1mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of study medication once daily in each eye at bedtime during 90 days.
Trial: NCT03541655
Drug: F14 (celecoxib)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib in novel drug delivery system (BEPO™)
Trial: NCT04019652
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, oral administration; 10-mg or 40-mg dose
Trial: NCT04019652
Drug: Placebo matching CS-3150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching CS-3150 tablets
Trial: NCT01790009
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x500 mg Acetaminophen
Trial: NCT02483078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02483078
Drug: Optimized Background Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Trial: NCT04178135
Drug: rLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH supplement from day 1 of stimulation
Trial: NCT04178135
Drug: rLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH supplement from day 6 of stimulation
Trial: NCT04470128
Drug: Stage I: HSK21542 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT04470128
Drug: Stage I: HSK21542 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT04470128
Drug: HSK21542 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT04470128
Drug: HSK21542 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT04470128
Drug: HSK21542 2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT04470128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT01299610
Drug: GW870086 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly colored opaque cream
Trial: NCT01299610
Drug: GW870086 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly colored opaque cream
Trial: NCT01299610
Drug: FP 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White cream
Trial: NCT04255277
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Trial: NCT02963896
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
Trial: NCT01975246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching hydrochlorothiazide tablet
Trial: NCT03516955
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Superstat ® Tablets 10mg, 20mg
Trial: NCT02919735
Drug: Placebo cutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
Trial: NCT02581865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no